Long-term follow-up of Ru-106/Rh-106 brachytherapy for posterior uveal melanoma

Lommatzsch, P; Werschnik, Cornelia; Schuster, Ernst

doi:10.1007/pl00007880

Cited by 150 publications

(82 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For tumours higher than 8 mm treated by iodine, cobalt, iridium, or ruthenium, a 5-year probability for retaining vision better than 0.1 of 43% has been found [17]. Lommatzsch found for ruthenium brachytherapy a 10-year probability for visual acuity of 0.1 or better of 37% [18]. In the COMS the 3-year probability for retaining vision of better than 0.1 was 57% and for not losing 6 lines 51% [14].…”

Section: Visual Acuitymentioning

confidence: 99%

“…The eyes with local recurrence were almost all enucleated with postoperative vision set at no light perception. In the literature, the risk factors for visual acuity loss are higher-age, poor initial visual acuity, increasing tumour height, proximity to fovea or optic disc, anterior tumour margin posterior to the equator, presence of subretinal fluid, and tumour recurrence [14Á/ 16,18,19,24,32,34,35] .…”

Section: Visual Acuitymentioning

confidence: 99%

See 1 more Smart Citation

Visual outcome, local tumour control, and eye preservation after¹⁰⁶Ru/Rh brachytherapy for choroidal melanoma

et al. 2006

View full text Add to dashboard Cite

Section: Visual Acuitymentioning

confidence: 99%

Section: Visual Acuitymentioning

confidence: 99%

Visual outcome, local tumour control, and eye preservation after¹⁰⁶Ru/Rh brachytherapy for choroidal melanoma

et al. 2006

View full text Add to dashboard Cite

“…[12][13][14] We encountered two cases in which tumour activity became evident by direct observation during vitrectomy for non-clearing vitreous haemorrhage. These were treated at the time with endolaser, but both cases ultimately required enucleation.…”

Section: Discussionmentioning

confidence: 99%

Incidence and indications for pars plana vitrectomy following the treatment of posterior uveal melanomas in Scotland

Chia

Smith

Hammer

et al. 2015

Eye

View full text Add to dashboard Cite

Background Globe-sparing treatments such as plaque brachytherapy, local or endoresection, and proton beam therapy (PBT) are the treatments of choice for posterior uveal melanoma. However, both early and late complications can arise from these techniques, including vitreous haemorrhage (VH) and retinal detachment (RD). Choroidal melanomas in Scotland are managed by a single unit, the Scottish Ocular Oncology Service (SOOS). Methods Indications and outcomes from surgery were analysed for patients undergoing vitrectomy following treatment for uveal melanoma in the SOOS between 1998 and 2013. Results Seventeen from 715 cases (2.4%) required vitrectomy, of which 8/445 (1.8%) followed plaque brachytherapy, 7/43 (16.3%) combined local resection and brachytherapy, and 2/227 (0.9%) PBT. Casenotes were reviewed for 16/17 cases, with surgery indicated for VH in 10 (63%), RD in 5 (31%), and combined VH/RD in 1 (6%). The median interval from initial tumour treatment to vitrectomy was 5.8 months (range 10 days to 8.8 years). Ten (63%) required early vitrectomy (within 6 months), of which the majority (70%) followed combined resection/ brachytherapy. Six (37%) required late vitrectomy (after 6 months), of which all were non-clearing VH following plaque brachytherapy, with proliferative retinopathy in 4/6 (67%), and tumour recurrence in 2/6 (33%). Overall vision improved in 8 eyes (50%), remained the same in 2 (12.5%), and deteriorated in 6 (37.5%). Conclusions Early vitrectomy was most commonly indicated for RD following local resection, and late vitrectomy for VH due to radiation retinopathy. The majority of

show abstract

“…3 106 Ru has been primarily used in the treatment of choroidal melanoma. 4,5 Penetration depends on the energy of particles released in the decay process of a particular source. Of emitters used in ophthalmology, the 90 Sr source has the most marked attenuation in biological tissues, making it particularly suitable for use in ocular surface treatment.…”

Section: Beta Radiationmentioning

confidence: 99%

Beta irradiation: new uses for an old treatment: a review

Kirwan¹,

Constable

Murdoch

et al. 2003

Eye

View full text Add to dashboard Cite

Beta radiation has a long history as a treatment modality in ophthalmology. It is a convenient and practical method of applying radiation and has the advantage of minimal tissue penetration. There has been a recent resurgence in the use of beta radiation in other areas in medicine, such as the prevention of restenosis after coronary artery stenting. Beta radiation has been shown in vitro and in vivo to inhibit proliferation of human Tenon's fibroblasts, which enter a period of growth arrest but do not die. Effects on the cell cycle controller p53 have been shown to be important in this process.In ophthalmology, beta radiation has been used widely for the treatment of pterygium and is under evaluation for treatment of agerelated macular degeneration and for controlling wound healing after glaucoma drainage surgery. In this latter role, beta radiation may be particularly appropriate for use in developing countries to improve the results of trabeculectomy while potentially avoiding some of the side effects of other antimetabolites.

show abstract

Long-term follow-up of Ru-106/Rh-106 brachytherapy for posterior uveal melanoma

Cited by 150 publications

References 14 publications

Visual outcome, local tumour control, and eye preservation after¹⁰⁶Ru/Rh brachytherapy for choroidal melanoma

Visual outcome, local tumour control, and eye preservation after¹⁰⁶Ru/Rh brachytherapy for choroidal melanoma

Incidence and indications for pars plana vitrectomy following the treatment of posterior uveal melanomas in Scotland

Beta irradiation: new uses for an old treatment: a review

Contact Info

Product

Resources

About

Long-term follow-up of Ru-106/Rh-106 brachytherapy for posterior uveal melanoma

Cited by 150 publications

References 14 publications

Visual outcome, local tumour control, and eye preservation after106Ru/Rh brachytherapy for choroidal melanoma

Visual outcome, local tumour control, and eye preservation after106Ru/Rh brachytherapy for choroidal melanoma

Incidence and indications for pars plana vitrectomy following the treatment of posterior uveal melanomas in Scotland

Beta irradiation: new uses for an old treatment: a review

Contact Info

Product

Resources

About

Visual outcome, local tumour control, and eye preservation after¹⁰⁶Ru/Rh brachytherapy for choroidal melanoma

Visual outcome, local tumour control, and eye preservation after¹⁰⁶Ru/Rh brachytherapy for choroidal melanoma